74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Capricor Therapeutics Inc
Closed
15.03 -0.46
Overview
Share price change
24h
Min
14.91
Max
15.07
Income | -1.6M -13M |
|---|---|
Sales | -1.7M 2.3M |
EPS | -0.38 |
Profit margin | -555.204 |
Employees | 101 |
EBITDA | -1.4M -13M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +193.33 upside |
Next Earnings | 28 Feb 2025 |
|---|
Market Cap | 686M |
|---|---|
Previous open | 15.49 |
Previous close | 15.03 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Capricor Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Capricor Therapeutics Inc Forecast
Price Target
By TipRanks
193.33% upside
12 Months Forecast
Average 44 USD 193.33%
High 77 USD
Low 25 USD
Based on 5 Wall Street analysts offering 12 month price targets forCapricor Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.
